Setipiprant
DrugSetipiprant tablets, orally, BID for 24 weeks.
Other names: KYTH-105, AGN-241679
NCT Number: NCT02781311
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Looking for future studies?
Notify Me18 year–49 year
Male
Interventional
Phase 2
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Setipiprant tablets, orally, BID for 24 weeks.
Other names: KYTH-105, AGN-241679
Placebo tablets, orally, BID for 24 weeks.
Finasteride tablet, orally, once daily for 24 weeks.
Time frame: Baseline (Day 1) to Week 24
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
Time frame: Week 24
The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.
Allergan
Industry
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07271212
Alopecia, Hair Condition
Taichung, Taiwan
View Trial DetailsNCT07615608
Alopecia, Androgenetic Alopecia
Barcelona, Spain
View Trial DetailsNCT04492800
Alopecia, Hair Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial Details